Month: May 2025

In this exclusive PC Podcast interview, Alice Valder Curran, partner at Hogan Lovells, explores: How recent executive orders—both under the Biden and Trump administrations—have reshaped the drug pricing landscape, and the legal challenges or uncertainties they present for pharmaceutical companies What life sciences companies should be doing now to proactively prepare for further executive action on drug […]

In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for this disconnect. First, many companies […]

Image Credit: Adobe Stock Images/PostModernStudio.com Key Takeaways Full interchangeability approved: The FDA has granted full interchangeability to Hadlima for all Humira formulations, allowing pharmacist substitution without prescriber consultation (per state law). Expanded patient access: This designation may significantly reduce out-of-pocket costs and improve access to biologic therapies for patients across multiple chronic conditions. Clinical equivalence […]

In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for this disconnect. First, many companies […]

Image Credit: Adobe Stock Images/Feodora.com Main Takeaways The merger of Mercalis and PharmaCord, backed by Permira and Odyssey Investment Partners, forms Valeris—a platform aimed at streamlining how life sciences companies bring therapies to market through integrated patient support, data, and provider engagement tools. Valeris intends to transform the commercialization process by improving patient access, reducing […]

The pharmaceutical industry stands at the threshold of a long-overdue transformation in how serialization is approached, implemented, and managed. For more than a decade, serialization has largely been driven by compliance, delivering solutions that meet regulatory requirements but offer limited value beyond the legal minimum. Today, however, the world of pharmaceutical serialization is poised for […]

Temperature-Sensitive Tech: Cold Chain's Continuous Development

PC: You recently delivered a keynote presentation surrounding “How to Integrate E2E and Deliver ‘Miracles of Science’ to your Patients.” Could you provide a brief synopsis of what your session entailed? Beadle: Sanofi is undergoing a major transformation with the ambition to become the first biopharma company powered by AI at scale. To achieve that, […]

Key Takeaways Personalized medicine demands precision logistics, with strict temperature control, real-time tracking, and regulatory compliance essential to ensure safe and timely delivery of patient-specific therapies. Gaps in last-mile delivery and third-party training pose serious risks, especially when handling temperature-sensitive, irreplaceable treatments for critically ill patients. Advanced technologies like predictive analytics and smart packaging are […]

HPV Vaccine: Balancing Benefits, Risks, and Public Perception Despite ongoing lawsuits and public concerns about serious adverse events, current evidence supports the safety and effectiveness of the human papillomavirus vaccine in preventing a wide range of cancers, underscoring the need for continued public health advocacy and open patient-provider communication. Pfizer-backed CellCentric secures $120M for further […]

In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal from the consistent decline seen […]

Image Credit: Adobe Stock Images/PeterHansen.com Key Takeaways Noom is now offering its own compounded version of semaglutide—an active ingredient in Wegovy and Ozempic—through its telehealth marketplace. The FDA has ended the semaglutide shortage and set a May 22 deadline for compounders to cease production. Noom argues for a “personalized” exception, but it’s unclear how the […]

PC: How would you define successful E2E, and what specific processes are necessary in order to achieve this? Beadle: The first thing I’d highlight—and I mentioned this in the keynote—is that we are a company of scale and history. It’s hard to visualize that scale without digitization. We’ve moved away from Excel and connected our […]

Bridging Innovation and Trust with Artificial Intelligence In a recent interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, discussed how AI is transforming clinical trials by reducing costs, accelerating timelines, and enhancing patient inclusion—while emphasizing the need for data quality, transparency, and trust to ensure responsible implementation. AZ partners with Aptar […]

Credit: Production Perig | stock.adobe.com Key Takeaways Embrace Real-Time Data for Proactive Supply Chain Management. Advanced manufacturing and real-time analytics help pharmaceutical companies predict and prevent drug shortages. Just like in retail, real-time demand tracking and inventory optimization ensure essential medications are available when needed. Leverage Automation and AI for Resilience and Efficiency. Automated systems […]

The Role of AI in Solving Clinical Trial Diversity and Access Challenges In an interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, explained how AI can help address clinical trial diversity and access challenges by reducing physician workload through treatment matching, simplifying patient education, and breaking down logistical and informational barriers […]

PC: How do you see the potential impact of HHS’s proposed policy change on patient advocacy efforts, particularly for rare and serious diseases? Leuchter: If I step back and think about how critical it is to receive input, feedback, and partnership from patient advocates—their voice is truly essential—it’s hard to overstate. At Neurvati and GRIN, […]